Ethical Equities CUV writeup, page-2

That is easily the most accurate summary of the Clinuvel story that I have read. Previous authors of recent times, Sphene capital and Tim Boreham have made errors or just missed part of the story. This is not necessarily a criticism as Clinuvel have no investor relations and refuse to speak with journalists or analysts as I expect was the case here also. My only criticism on first reading was the the claim that Clinuvel have a patent for neuro conditions. My understanding is that this patent was not granted.

Clinuvel remains a compelling growth story for the patient investor. FDA approval will be the true growth stimulus and that may still be some months away. EMA approval took 2 1/2 years from complete dossier submission. Clinuvel haven't even got to complete dossier submission point with the FDA yet.

The share price run of the last few days is holding up remarkably well with the highest volume in forever.